{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:49:15Z","timestamp":1794433755795,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96427-3","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T05:45:35Z","timestamp":1743831935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Jinlong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"96427_CR1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.24976\/Discov.Med.202335178.65","volume":"35","author":"A Pokhrel","year":"2023","unstructured":"Pokhrel, A. et al. Association between prostate carcinoma and multiple myeloma. Discov. Med. 35, 664\u2013672. https:\/\/doi.org\/10.24976\/Discov.Med.202335178.65 (2023).","journal-title":"Discov. Med."},{"key":"96427_CR2","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/ijc.33762","volume":"149","author":"K Hemminki","year":"2021","unstructured":"Hemminki, K., Forsti, A., Houlston, R. & Sud, A. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. Int. J. Cancer 149, 1980\u20131996. https:\/\/doi.org\/10.1002\/ijc.33762 (2021).","journal-title":"Int. J. Cancer"},{"key":"96427_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle, R. A. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21\u201333. https:\/\/doi.org\/10.4065\/78.1.21 (2003).","journal-title":"Mayo Clin. Proc."},{"key":"96427_CR4","doi-asserted-by":"publisher","first-page":"846310","DOI":"10.3389\/fendo.2022.846310","volume":"13","author":"A Gilchrist","year":"2022","unstructured":"Gilchrist, A. & Echeverria, S. L. Targeting chemokine receptor CCR1 as a potential therapeutic approach for multiple myeloma. Front. Endocrinol. (Lausanne) 13, 846310. https:\/\/doi.org\/10.3389\/fendo.2022.846310 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"96427_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1136\/jitc-2020-000734","volume":"8","author":"N Shah","year":"2020","unstructured":"Shah, N. et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J. Immunother. Cancer 8, 734. https:\/\/doi.org\/10.1136\/jitc-2020-000734 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"96427_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3238\/arztebl.2016.0470","volume":"113","author":"C Gerecke","year":"2016","unstructured":"Gerecke, C. et al. The diagnosis and treatment of multiple myeloma. Dtsch. Arztebl Int. 113, 470\u2013476. https:\/\/doi.org\/10.3238\/arztebl.2016.0470 (2016).","journal-title":"Dtsch. Arztebl Int."},{"key":"96427_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cancers12020265","volume":"12","author":"S Ito","year":"2020","unstructured":"Ito, S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers (Basel) 12, 265. https:\/\/doi.org\/10.3390\/cancers12020265 (2020).","journal-title":"Cancers (Basel)"},{"key":"96427_CR8","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P. et al. Oral Ixazomib, Lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 374, 1621\u20131634. https:\/\/doi.org\/10.1056\/NEJMoa1516282 (2016).","journal-title":"N Engl. J. Med."},{"key":"96427_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1078155212470388","volume":"19","author":"JM Steele","year":"2013","unstructured":"Steele, J. M. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma. J. Oncol. Pharm. Pract. 19, 348\u2013354. https:\/\/doi.org\/10.1177\/1078155212470388 (2013).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"96427_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 11, 3\u201310. https:\/\/doi.org\/10.1002\/pds.668 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"96427_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pds.1746","volume":"18","author":"E Poluzzi","year":"2009","unstructured":"Poluzzi, E., Raschi, E., Moretti, U. & De Ponti, F. Drug-induced Torsades de pointes: data mining of the public version of the FDA adverse event reporting system (AERS). Pharmacoepidemiol. Drug Saf. 18, 512\u2013518. https:\/\/doi.org\/10.1002\/pds.1746 (2009).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"96427_CR12","doi-asserted-by":"publisher","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","volume":"10","author":"Y Shu","year":"2022","unstructured":"Shu, Y. et al. Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Front. Public Health 10, 996179. https:\/\/doi.org\/10.3389\/fpubh.2022.996179 (2022).","journal-title":"Front. Public Health"},{"key":"96427_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita, S., Hosomi, K., Yokoyama, S. & Takada, M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J. Clin. Pharm. Ther. 45, 65\u201371. https:\/\/doi.org\/10.1111\/jcpt.13024 (2020).","journal-title":"J. Clin. Pharm. Ther."},{"key":"96427_CR14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","volume":"17","author":"G Cengiz Seval","year":"2018","unstructured":"Cengiz Seval, G. & Beksac, M. The safety of bortezomib for the treatment of multiple myeloma. Expert Opin. Drug Saf. 17, 953\u2013962. https:\/\/doi.org\/10.1080\/14740338.2018.1513487 (2018).","journal-title":"Expert Opin. Drug Saf."},{"key":"96427_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000519687","volume":"100","author":"S Nakao","year":"2022","unstructured":"Nakao, S. et al. Evaluation of cardiac adverse events associated with Carfilzomib using a Japanese real-world database. Oncology 100, 60\u201364. https:\/\/doi.org\/10.1159\/000519687 (2022).","journal-title":"Oncology"},{"key":"96427_CR16","doi-asserted-by":"publisher","first-page":"e000570","DOI":"10.1136\/esmoopen-2019-000570","volume":"4","author":"K Tzogani","year":"2019","unstructured":"Tzogani, K. et al. European medicines agency review of Ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open 4, e000570. https:\/\/doi.org\/10.1136\/esmoopen-2019-000570 (2019).","journal-title":"ESMO Open"},{"key":"96427_CR17","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/1078155220941937","volume":"27","author":"EP Borrelli","year":"2021","unstructured":"Borrelli, E. P. & McGladrigan, C. G. Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials. J. Oncol. Pharm. Pract. 27, 887\u2013896. https:\/\/doi.org\/10.1177\/1078155220941937 (2021).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"96427_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000524806","volume":"100","author":"K Yamaoka","year":"2022","unstructured":"Yamaoka, K. et al. Comprehensive analysis of ixazomib-induced adverse events using the Japanese pharmacovigilance database. Oncology 100, 413\u2013418. https:\/\/doi.org\/10.1159\/000524806 (2022).","journal-title":"Oncology"},{"key":"96427_CR19","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/jcph.719","volume":"56","author":"N Gupta","year":"2016","unstructured":"Gupta, N. et al. The effect of a high-fat meal on the pharmacokinetics of Ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma. J. Clin. Pharmacol. 56, 1288\u20131295. https:\/\/doi.org\/10.1002\/jcph.719 (2016).","journal-title":"J. Clin. Pharmacol."},{"key":"96427_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4274\/tjh.galenos.2021.2021.0052","volume":"38","author":"SA Mina","year":"2021","unstructured":"Mina, S. A. et al. Post-marketing analysis of peripheral neuropathy burden with new-generation proteasome inhibitors using the FDA adverse event reporting system. Turk. J. Haematol. 38, 218\u2013221. https:\/\/doi.org\/10.4274\/tjh.galenos.2021.2021.0052 (2021).","journal-title":"Turk. J. Haematol."},{"key":"96427_CR21","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson, P. G. et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. 24, 3113\u20133120. https:\/\/doi.org\/10.1200\/JCO.2005.04.7779 (2006).","journal-title":"J. Clin. Oncol."},{"key":"96427_CR22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","volume":"51","author":"G Cavaletti","year":"2010","unstructured":"Cavaletti, G. & Jakubowiak, A. J. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk. Lymphoma 51, 1178\u20131187. https:\/\/doi.org\/10.3109\/10428194.2010.483303 (2010).","journal-title":"Leuk. Lymphoma"},{"key":"96427_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.leukres.2009.07.022","volume":"34","author":"A Corso","year":"2010","unstructured":"Corso, A. et al. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk. Res. 34, 471\u2013474. https:\/\/doi.org\/10.1016\/j.leukres.2009.07.022 (2010).","journal-title":"Leuk. Res."},{"key":"96427_CR24","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","volume":"17","author":"S Arastu-Kapur","year":"2011","unstructured":"Arastu-Kapur, S. et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and Carfilzomib: a link to clinical adverse events. Clin. Cancer Res. 17, 2734\u20132743. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1950 (2011).","journal-title":"Clin. Cancer Res."},{"key":"96427_CR25","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1084\/jem.20170584","volume":"215","author":"K Stockstill","year":"2018","unstructured":"Stockstill, K. et al. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J. Exp. Med. 215, 1301\u20131313. https:\/\/doi.org\/10.1084\/jem.20170584 (2018).","journal-title":"J. Exp. Med."},{"key":"96427_CR26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/leu.2011.346","volume":"26","author":"PG Richardson","year":"2012","unstructured":"Richardson, P. G. et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26, 595\u2013608. https:\/\/doi.org\/10.1038\/leu.2011.346 (2012).","journal-title":"Leukemia"},{"key":"96427_CR27","doi-asserted-by":"publisher","first-page":"104353","DOI":"10.1016\/j.critrevonc.2024.104353","volume":"197","author":"Y Yang","year":"2024","unstructured":"Yang, Y., Zhao, B., Lan, H., Sun, J. & Wei, G. Bortezomib-induced peripheral neuropathy: clinical features, molecular basis, and therapeutic approach. Crit. Rev. Oncol. Hematol. 197, 104353. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104353 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"96427_CR28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00432-024-05716-3","volume":"150","author":"J Shah","year":"2024","unstructured":"Shah, J. et al. Gastrointestinal toxicities of proteasome inhibitor therapy. J. Cancer Res. Clin. Oncol. 150, 334. https:\/\/doi.org\/10.1007\/s00432-024-05716-3 (2024).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"96427_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12012-023-09785-7","volume":"23","author":"AT Jannuzzi","year":"2023","unstructured":"Jannuzzi, A. T. et al. Molecular cardiotoxic effects of proteasome inhibitors Carfilzomib and Ixazomib and their combination with dexamethasone involve mitochondrial dysregulation. Cardiovasc. Toxicol. 23, 121\u2013131. https:\/\/doi.org\/10.1007\/s12012-023-09785-7 (2023).","journal-title":"Cardiovasc. Toxicol."},{"key":"96427_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000500976","volume":"143","author":"O Alkharabsheh","year":"2020","unstructured":"Alkharabsheh, O., Sidiqi, M. H., Aljama, M. A., Gertz, M. A. & Frankel, A. E. The human microbiota in multiple myeloma and proteasome inhibitors. Acta Haematol. 143, 118\u2013123. https:\/\/doi.org\/10.1159\/000500976 (2020).","journal-title":"Acta Haematol."},{"key":"96427_CR31","doi-asserted-by":"publisher","unstructured":"Huber, E. M., Heinemeyer, W. & Groll, M. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914. Structure 23, 407\u2013417. https:\/\/doi.org\/10.1016\/j.str.2014.11.019 (2015).","DOI":"10.1016\/j.str.2014.11.019"},{"key":"96427_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1183\/13993003.02158-2023","volume":"63","author":"J Grynblat","year":"2024","unstructured":"Grynblat, J. et al. Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors. Eur. Respir. J. 63, 23. https:\/\/doi.org\/10.1183\/13993003.02158-2023 (2024).","journal-title":"Eur. Respir. J."},{"key":"96427_CR33","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.2217\/fon-2022-0259","volume":"18","author":"A Kawasaki","year":"2022","unstructured":"Kawasaki, A., Murakami, H., Chou, T., Matsushita, M. & Kizaki, M. Post-marketing surveillance of Carfilzomib in Japanese patients with relapsed or refractory multiple myeloma. Future Oncol. 18, 2661\u20132674. https:\/\/doi.org\/10.2217\/fon-2022-0259 (2022).","journal-title":"Future Oncol."},{"key":"96427_CR34","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau, P. et al. Once weekly versus twice weekly Carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 19, 953\u2013964. https:\/\/doi.org\/10.1016\/S1470-2045(18)30354-1 (2018).","journal-title":"Lancet Oncol."},{"key":"96427_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40262-018-0702-1","volume":"58","author":"N Gupta","year":"2019","unstructured":"Gupta, N. et al. Clinical Pharmacology of Ixazomib: the first oral proteasome inhibitor. Clin. Pharmacokinet. 58, 431\u2013449. https:\/\/doi.org\/10.1007\/s40262-018-0702-1 (2019).","journal-title":"Clin. Pharmacokinet."},{"key":"96427_CR36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/DDDT.S93602","volume":"10","author":"B Muz","year":"2016","unstructured":"Muz, B. et al. Spotlight on Ixazomib: potential in the treatment of multiple myeloma. Drug Des. Dev. Ther. 10, 217\u2013226. https:\/\/doi.org\/10.2147\/DDDT.S93602 (2016).","journal-title":"Drug Des. Dev. Ther."},{"key":"96427_CR37","first-page":"1","volume":"1","author":"SK Kumar","year":"2022","unstructured":"Kumar, S. K. et al. The mydrug platform trial: efficacy and safety of daratumumab, Ixazomib, Pomalidomide, and dexamethasone in patients with functionally high-risk multiple myeloma. Blood 1, 1 (2022).","journal-title":"Blood"},{"key":"96427_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/MEG.0b013e32811ebffe","volume":"19","author":"V Perfetti","year":"2007","unstructured":"Perfetti, V. et al. Bortezomib-induced paralytic ileus is a potential Gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor. Eur. J. Gastroenterol. Hepatol. 19, 599\u2013601. https:\/\/doi.org\/10.1097\/MEG.0b013e32811ebffe (2007).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"96427_CR39","first-page":"760","volume":"53","author":"Y Koda","year":"2012","unstructured":"Koda, Y. et al. Early onset of paralytic ileus caused by simultaneous administration of bortezomib and Azole antifungals in multiple myeloma patients. Rinsho Ketsueki 53, 760\u2013764 (2012).","journal-title":"Rinsho Ketsueki"},{"key":"96427_CR40","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.2022016782","volume":"141","author":"B Paiva","year":"2023","unstructured":"Paiva, B. et al. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood 141, 579\u2013591. https:\/\/doi.org\/10.1182\/blood.2022016782 (2023).","journal-title":"Blood"},{"key":"96427_CR41","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96427-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96427-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96427-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T05:45:53Z","timestamp":1743831953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96427-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96427"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96427-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"5 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11628"}}